|
287 Companies |
|
339 Products |
|
339 Products |
|
208 Mechanisms of Action |
|
11 Trials |
|
3331 News |
|
| «12...57585960616263646566676869» |
- Trial completion: Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast (clinicaltrials.gov) - Nov 2, 2011
P2, N=42, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Completed
- New P1 trial: NPEF: Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer (clinicaltrials.gov) - Oct 31, 2011
P1, N=4, Completed, Sponsor: Children's Hospital & Research Center Oakland
- Sutent (sunitinib) / Pfizer
Trial completion: Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=50, Completed, Sponsor: Radboud University
Recruiting --> Completed Recruiting --> Completed
- Enrollment change: B-Receptor Signaling in Cardiomyopathy (clinicaltrials.gov) - Oct 30, 2011
P=N/A, N=99, Completed, Sponsor: Daniel Bernstein
Recruiting --> Completed N=300 --> 99
- dovitinib (TKI258) / Novartis, Oncoheroes
Enrollment open, Monotherapy: Dovitinib in Adenoid Cystic Carcinoma (clinicaltrials.gov) - Oct 30, 2011
P2, N=33, Recruiting, Sponsor: Seoul National University Hospital
N=300 --> 99 Not yet recruiting --> Recruiting
- Trial completion: B-Receptor Signaling in Cardiomyopathy (clinicaltrials.gov) - Oct 30, 2011
P=N/A, N=99, Completed, Sponsor: Daniel Bernstein
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Stimuvax (tecemotide) / EMD Serono, Ono Pharma
New P2 trial: L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases (clinicaltrials.gov) - Oct 27, 2011
P2, N=159, Recruiting, Sponsor: Dr. Carl Schimanski
- | famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P1 trial, Metastases: FMTN-I-LNPC: Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov) - Oct 26, 2011
P1, N=21, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Trial completion: Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme (clinicaltrials.gov) - Oct 25, 2011
P1, N=0, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Recruiting --> Completed Active, not recruiting --> Completed
- DC Bead (E7040) / Eisai, Boston Scientific
Enrollment change: The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead (clinicaltrials.gov) - Oct 24, 2011
P=N/A, N=5, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed N=25 --> 5
- New P1 trial, Metastases: STALLO: Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors (clinicaltrials.gov) - Oct 24, 2011
P1, N=10, Recruiting, Sponsor: Children's Mercy Hospital Kansas City
- oxaliplatin / Generic mfg.
Enrollment change, Metastases: Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer (clinicaltrials.gov) - Oct 20, 2011
P1, N=16, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
N=25 --> 5 N=60 --> 16
- oxaliplatin / Generic mfg.
Trial completion, Metastases: Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer (clinicaltrials.gov) - Oct 20, 2011
P1, N=16, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
N=60 --> 16 Active, not recruiting --> Completed
- CP-870893 / Pfizer
New P1 trial: Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma (clinicaltrials.gov) - Oct 19, 2011
P1, N=10, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- temozolomide / Generic mfg.
Enrollment change: Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide (clinicaltrials.gov) - Oct 18, 2011
P1/2, N=26, Completed, Sponsor: AHS Cancer Control Alberta
Active, not recruiting --> Completed N=15 --> 26
- ||||| apitolisib (GDC-0980) / Roche
New P2 trial: A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma (clinicaltrials.gov) - Oct 18, 2011
P2, N=56, Active, not recruiting, Sponsor: Genentech
- Trial completion, Tumor cell: Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma (clinicaltrials.gov) - Oct 18, 2011
P=N/A, N=19, Completed, Sponsor: University of Kansas
N=15 --> 26 Active, not recruiting --> Completed
- temozolomide / Generic mfg.
Trial completion: Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide (clinicaltrials.gov) - Oct 18, 2011
P1/2, N=26, Completed, Sponsor: AHS Cancer Control Alberta
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| apatorsen (OGX-427) / Achieve Life Sciences
New P2 trial, Combination therapy, Metastases: A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer (clinicaltrials.gov) - Oct 16, 2011
P2, N=180, Active, not recruiting, Sponsor: OncoGenex Technologies
- ||||| Avastin (bevacizumab) / Roche
Enrollment closed, Combination therapy: BO21990: A Study of Bevacizumab (Avastin (clinicaltrials.gov) - Oct 13, 2011
P3, N=921, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial completion: Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - Oct 13, 2011
P2, N=41, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| BMS-908662 / Exelixis
Trial completion: Study of XL281 in Adults With Solid Tumors (clinicaltrials.gov) - Oct 11, 2011
P1, N=180, Completed, Sponsor: Exelixis
Active, not recruiting --> Completed Recruiting --> Completed
- Farydak (panobinostat) / Secura Bio
Trial withdrawal, Surgery, Pre-surgery: CLBH589C: A Panobinostat Presurgery (clinicaltrials.gov) - Oct 10, 2011
P2, N=0, Withdrawn, Sponsor: Duke University
Recruiting --> Completed Recruiting --> Withdrawn
- | thalidomide / Generic mfg.
Trial termination, Metastases: Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve (clinicaltrials.gov) - Oct 10, 2011
P3, N=230, Terminated, Sponsor: TTY Biopharm
Recruiting --> Withdrawn Recruiting --> Terminated; slowly recruitment rate
- || New P3 trial: Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme (clinicaltrials.gov) - Oct 10, 2011
P3, N=159, Active, not recruiting, Sponsor: International Atomic Energy Agency
- ||||| ondansetron / Generic mfg., temozolomide / Generic mfg.
New P2 trial, Combination therapy, CINV: Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide (clinicaltrials.gov) - Oct 10, 2011
P2, N=136, Recruiting, Sponsor: Katy Peters
- mitomycin / Generic mfg., doxorubicin hydrochloride / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Combination therapy, Surgery: Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Oct 10, 2011
P1, N=11, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Terminated; slowly recruitment rate Recruiting --> Active, not recruiting
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment open, Combination therapy, PARP Biomarker, IO biomarker: CRUK-CR0901-11: Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma (clinicaltrials.gov) - Oct 6, 2011
P1, N=34, Recruiting, Sponsor: Cancer Research UK
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial termination: Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer (clinicaltrials.gov) - Oct 5, 2011
P1/2, N=20, Terminated, Sponsor: University Health Network, Toronto
Not yet recruiting --> Recruiting Recruiting --> Terminated; Poor recruitment
- Enrollment closed: Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy (clinicaltrials.gov) - Oct 5, 2011
P=N/A, N=12, Active, not recruiting, Sponsor: Loma Linda University
Recruiting --> Terminated; Poor recruitment Recruiting --> Active, not recruiting
- cisplatin / Generic mfg., azacitidine / Generic mfg.
Enrollment closed, Combination therapy, Metastases: Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer (clinicaltrials.gov) - Oct 5, 2011
P1, N=24, Active, not recruiting, Sponsor: Loma Linda University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Vectibix (panitumumab) / Amgen
Trial withdrawal: Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab (clinicaltrials.gov) - Oct 4, 2011
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- ||||| seribantumab (MM-121) / Elevation Oncology
New P2 trial: A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers (clinicaltrials.gov) - Oct 4, 2011
P2, N=210, Active, not recruiting, Sponsor: Merrimack Pharmaceuticals
- ||| CEP-37250 / Teva, Kyowa Kirin
New P1 trial, Metastases: Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Oct 4, 2011
P1, N=74, Recruiting, Sponsor: Kyowa Hakko Kirin Pharma, Inc.
- Trial completion, Biopsy: PRO-STATE:Search for a Protein Profile Corresponding to Fast-developing Lesions and Characterization of Implicated Proteins in Prostate Carcinoma (clinicaltrials.gov) - Oct 4, 2011
P=N/A, N=300, Completed, Sponsor: University Hospital, Grenoble
Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- imatinib / Generic mfg., everolimus / Generic mfg.
Enrollment change, Combination therapy, Metastases: Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer (clinicaltrials.gov) - Oct 3, 2011
P2, N=23, Completed, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed N=43 --> 23
- Votrient (pazopanib) / Novartis
Observational data: Cardiovascular and Torsades de Pointes Monitoring for Pazopanib (clinicaltrials.gov) - Oct 3, 2011
P=N/A, N=1, Active, not recruiting, Sponsor: GlaxoSmithKline
- New P1/2 trial: Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma (clinicaltrials.gov) - Oct 3, 2011
P1/2, N=40, Completed, Sponsor: Xiangya Hospital of Central South University
- imatinib / Generic mfg., everolimus / Generic mfg.
Trial completion, Combination therapy, Metastases: Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer (clinicaltrials.gov) - Oct 3, 2011
P2, N=23, Completed, Sponsor: OHSU Knight Cancer Institute
N=43 --> 23 Active, not recruiting --> Completed
- | Enrollment change, Biopsy: Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion (clinicaltrials.gov) - Oct 2, 2011
P3, N=103, Completed, Sponsor: Oswaldo Cruz Foundation
Active, not recruiting --> Completed N=366 --> 103
- | New P2 trial, Surgery: More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery (clinicaltrials.gov) - Oct 2, 2011
P2, N=60, Recruiting, Sponsor: Emory University
- | Trial completion, Biopsy: Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion (clinicaltrials.gov) - Oct 2, 2011
P3, N=103, Completed, Sponsor: Oswaldo Cruz Foundation
N=366 --> 103 Recruiting --> Completed
- Enrollment open: Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck (clinicaltrials.gov) - Sep 28, 2011
P2, N=100, Recruiting, Sponsor: University Hospital, Ghent
Recruiting --> Completed Not yet recruiting --> Recruiting
- | BIIB022 / Biogen
Trial completion, Metastases: Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Sep 28, 2011
P1, N=40, Completed, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| apitolisib (GDC-0980) / Roche
New P2 trial, Metastases: Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy (clinicaltrials.gov) - Sep 26, 2011
P2, N=85, Active, not recruiting, Sponsor: Genentech
- Enrollment closed: Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC) (clinicaltrials.gov) - Sep 26, 2011
P=N/A, N=25, Active, not recruiting, Sponsor: Angiodynamics, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change: Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection (clinicaltrials.gov) - Sep 21, 2011
P2, N=20, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting N=30 --> 20
- || New P3 trial: Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients (clinicaltrials.gov) - Sep 21, 2011
P3, N=94, Completed, Sponsor: Instituto Nacional de Cancer, Brazil
- | letrozole / Generic mfg.
New P2 trial: DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Sep 21, 2011
P2, N=115, Recruiting, Sponsor: Cancer and Leukemia Group B
- New P2 trial: FES-PET to Determine ER-expression in Epithelial Ovarian Cancer (clinicaltrials.gov) - Sep 21, 2011
P2, N=15, Completed, Sponsor: University Medical Centre Groningen